{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:26:47Z","timestamp":1792009607655,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We performed molecular dynamics simulation of the dimeric SARS-CoV-2 (severe acute respiratory syndrome corona virus 2) main protease (M\n                    <jats:sup>pro<\/jats:sup>\n                    ) to examine the binding dynamics of small molecular ligands. Seven HIV inhibitors, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir, were used as the potential lead drugs to investigate access to the drug binding sites in M\n                    <jats:sup>pro<\/jats:sup>\n                    . The frequently accessed sites on M\n                    <jats:sup>pro<\/jats:sup>\n                    were classified based on contacts between the ligands and the protein, and the differences in site distributions of the encounter complex were observed among the ligands. All seven ligands showed binding to the active site at least twice in 28 simulations of 200\u00a0ns each. We further investigated the variations in the complex structure of the active site with the ligands, using microsecond order simulations. Results revealed a wide variation in the shapes of the binding sites and binding poses of the ligands. Additionally, the C-terminal region of the other chain often interacted with the ligands and the active site. Collectively, these findings indicate the importance of dynamic sampling of protein\u2013ligand complexes and suggest the possibilities of further drug optimisations.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-74099-5","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T06:02:42Z","timestamp":1602482562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation"],"prefix":"10.1038","volume":"10","author":[{"given":"Teruhisa S.","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei M.","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentaro","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Taiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"74099_CR1","unstructured":"Share Chemistry\u2014American Chemical Society. https:\/\/www.acs.org\/content\/acs\/en\/covid-19\/share-chemistry.html."},{"key":"74099_CR2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00319","author":"RE Amaro","year":"2020","unstructured":"Amaro, R. E. & Mulholland, A. J. A community letter regarding sharing bimolecular simulation data for COVID-19. J. Chem. Inf. Model. https:\/\/doi.org\/10.1021\/acs.jcim.0c00319 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"74099_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2223-y","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature https:\/\/doi.org\/10.1038\/s41586-020-2223-y (2020).","journal-title":"Nature"},{"key":"74099_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3405","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science https:\/\/doi.org\/10.1126\/science.abb3405 (2020).","journal-title":"Science"},{"key":"74099_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-0440-6","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat. Struct. Mol. Biol. https:\/\/doi.org\/10.1038\/s41594-020-0440-6 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74099_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0356-z","author":"C Ma","year":"2020","unstructured":"Ma, C. et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. https:\/\/doi.org\/10.1038\/s41422-020-0356-z (2020).","journal-title":"Cell Res."},{"key":"74099_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb4489","author":"W Dai","year":"2020","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science https:\/\/doi.org\/10.1126\/science.abb4489 (2020).","journal-title":"Science"},{"key":"74099_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16954-7","author":"DW Kneller","year":"2020","unstructured":"Kneller, D. W. et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-020-16954-7 (2020).","journal-title":"Nat. Commun."},{"key":"74099_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2001282 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74099_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.04.083","author":"N Yamamoto","year":"2004","unstructured":"Yamamoto, N. et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. https:\/\/doi.org\/10.1016\/j.bbrc.2004.04.083 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"74099_CR11","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22457.1","author":"YW Chen","year":"2020","unstructured":"Chen, Y. W., Yiu, C. P. B. & Wong, K. Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.22457.1 (2020).","journal-title":"F1000Res."},{"key":"74099_CR12","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.14.039925","author":"H Ohashi","year":"2020","unstructured":"Ohashi, H. et al. Multidrug treatment with nelfinavir and cepharanthine against COVID-19. bioRxiv https:\/\/doi.org\/10.1101\/2020.04.14.039925 (2020).","journal-title":"bioRxiv"},{"key":"74099_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.06.026476","author":"N Yamamoto","year":"2020","unstructured":"Yamamoto, N., Matsuyama, S., Hoshino, T. & Yamamoto, N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv https:\/\/doi.org\/10.1101\/2020.04.06.026476 (2020).","journal-title":"bioRxiv"},{"key":"74099_CR14","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.11847381","author":"A Contini","year":"2020","unstructured":"Contini, A. Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins. ChemRxiv https:\/\/doi.org\/10.26434\/chemrxiv.11847381 (2020).","journal-title":"ChemRxiv"},{"key":"74099_CR15","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12003930.v3","author":"A Farag","year":"2020","unstructured":"Farag, A., Wang, P., Ahmed, M. & Sadek, H. Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning. ChemRxiv https:\/\/doi.org\/10.26434\/chemrxiv.12003930.v3 (2020).","journal-title":"ChemRxiv"},{"key":"74099_CR16","doi-asserted-by":"publisher","DOI":"10.1039\/d0ra01899f","author":"P Sang","year":"2020","unstructured":"Sang, P., Tian, S. H., Meng, Z. H. & Yang, L. Q. Anti-HIV drug repurposing against SARS-CoV-2. RSC Adv. https:\/\/doi.org\/10.1039\/d0ra01899f (2020).","journal-title":"RSC Adv."},{"key":"74099_CR17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00491","author":"ST Ngo","year":"2020","unstructured":"Ngo, S. T., Quynh Anh Pham, N., Thi Le, L., Pham, D.-H. & Vu, V. V. Computational determination of potential inhibitors of SARS-CoV-2 main protease. J. Chem. Inf. Model. https:\/\/doi.org\/10.1021\/acs.jcim.0c00491 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"74099_CR18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00326","author":"S Kumar","year":"2020","unstructured":"Kumar, S. et al. Discovery of new hydroxyethylamine analogs against 3CLpro protein target of SARS-CoV-2: molecular docking, molecular dynamics simulation, and structure-activity relationship studies. J. Chem. Inf. Model. https:\/\/doi.org\/10.1021\/acs.jcim.0c00326 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"74099_CR19","unstructured":"Komatsu, T. S. et al. Japanese published unexamined patent application no. 2020-64560 (JP 2020-64560A)."},{"key":"74099_CR20","doi-asserted-by":"publisher","unstructured":"ULC, C. C. G. Molecular Operating Environment (MOE), 2013.08. 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7 (2018). https:\/\/doi.org\/10.1038\/ja.2010.129.","DOI":"10.1038\/ja.2010.129"},{"key":"74099_CR21","doi-asserted-by":"publisher","DOI":"10.1021\/ar000033j","author":"PA Kollman","year":"2000","unstructured":"Kollman, P. A. et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. https:\/\/doi.org\/10.1021\/ar000033j (2000).","journal-title":"Acc. Chem. Res."},{"key":"74099_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.10379","author":"H Gohlke","year":"2004","unstructured":"Gohlke, H. & Case, D. A. Converging free energy estimates: MM-PB(GB)SA studies on the protein\u2013protein complex Ras-Raf. J. Comput. Chem. https:\/\/doi.org\/10.1002\/jcc.10379 (2004).","journal-title":"J. Comput. Chem."},{"key":"74099_CR23","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01828","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. \u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01828 (2020).","journal-title":"J. Med. Chem."},{"key":"74099_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1601327113","author":"T Muramatsu","year":"2016","unstructured":"Muramatsu, T. et al. SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity. Proc. Natl. Acad. Sci. U.S.A. https:\/\/doi.org\/10.1073\/pnas.1601327113 (2016).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"74099_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.28.922922","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. bioRxiv https:\/\/doi.org\/10.1101\/2020.01.28.922922 (2020).","journal-title":"bioRxiv"},{"key":"74099_CR26","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.27.921627","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv https:\/\/doi.org\/10.1101\/2020.01.27.921627 (2020).","journal-title":"bioRxiv"},{"key":"74099_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085658","author":"K Anand","year":"2003","unstructured":"Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science https:\/\/doi.org\/10.1126\/science.1085658 (2003).","journal-title":"Science"},{"key":"74099_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12222","author":"T Muramatsu","year":"2013","unstructured":"Muramatsu, T. et al. Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C-like protease (SARS-CoV 3CLpro) from its polyproteins. FEBS J. https:\/\/doi.org\/10.1111\/febs.12222 (2013).","journal-title":"FEBS J."},{"key":"74099_CR29","doi-asserted-by":"publisher","unstructured":"Berman, H. M. et al. The Protein Data Bank (https:\/\/www.rcsb.org). Nucleic Acids Res. (2000) doi:https:\/\/doi.org\/10.1093\/nar\/28.1.235.","DOI":"10.1093\/nar\/28.1.235"},{"key":"74099_CR30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jctc.5b00255","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. https:\/\/doi.org\/10.1021\/acs.jctc.5b00255 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"74099_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20035","author":"J Wang","year":"2004","unstructured":"Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general Amber force field. J. Comput. Chem. https:\/\/doi.org\/10.1002\/jcc.20035 (2004).","journal-title":"J. Comput. Chem."},{"key":"74099_CR32","unstructured":"Frisch, M. J. et al. Gaussian16 Revision C.01. Gaussian16 Revision C.01 (2016)."},{"key":"74099_CR33","doi-asserted-by":"publisher","DOI":"10.1021\/j100142a004","author":"CI Bayly","year":"1993","unstructured":"Bayly, C. I., Cieplak, P., Cornell, W. D. & Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. https:\/\/doi.org\/10.1021\/j100142a004 (1993).","journal-title":"J. Phys. Chem."},{"key":"74099_CR34","unstructured":"Cornell, W. D. et al. A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organic-molecules. J. Am. Chem. Soc. (1995)"},{"key":"74099_CR35","unstructured":"ParmEd\/ParmEd: parameter\/topology editor and molecular simulator. https:\/\/github.com\/ParmEd\/ParmEd."},{"key":"74099_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.softx.2015.06.001","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX https:\/\/doi.org\/10.1016\/j.softx.2015.06.001 (2015).","journal-title":"SoftwareX"},{"key":"74099_CR37","unstructured":"VMD\u2014Visual Molecular Dynamics. https:\/\/www.ks.uiuc.edu\/Research\/vmd\/."},{"key":"74099_CR38","unstructured":"Schrodinger\/pymol-open-source: Open-source foundation of the user-sponsored PyMOL molecular visualization system. https:\/\/github.com\/schrodinger\/pymol-open-source."},{"key":"74099_CR39","doi-asserted-by":"publisher","DOI":"10.1098\/rsta.2013.0387","author":"I Ohmura","year":"2014","unstructured":"Ohmura, I., Morimoto, G., Ohno, Y., Hasegawa, A. & Taiji, M. MDGRAPE-4: a special-purpose computer system formolecular dynamics simulations. Philos. Trans. R Soc. A Math. Phys. Eng. Sci. https:\/\/doi.org\/10.1098\/rsta.2013.0387 (2014).","journal-title":"Philos. Trans. R Soc. A Math. Phys. Eng. Sci."},{"key":"74099_CR40","doi-asserted-by":"publisher","unstructured":"Komatsu, T. S. et al. (2020) Molecular dynamics trajectories for SARS-CoV-2 Mpro with 7 HIV inhibitors. https:\/\/doi.org\/10.5281\/zenodo.3766083.","DOI":"10.5281\/zenodo.3766083"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74099-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74099-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74099-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T15:47:52Z","timestamp":1670341672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74099-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74099"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74099-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.12332678.v2","asserted-by":"object"},{"id-type":"doi","id":"10.26434\/chemrxiv.12332678.v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16986"}}